Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

2017 McDonald Criteria: CSF to Show Dissemination in Time

CSF Oligoclonal Bands as Prognostic Markers

Patient Case 1: Janna

Patient Case 1: Janna (cont)

MRI at Baseline and 6 Months: New Lesions

MRI: Presence of Black Holes

MRI as a Biomarker to Guide Treatment Decision: Clinician's Assessment of the Case

Risk Profiling Biomarkers: Anti-JC Virus Antibody Testing

Neurofilaments: From Detection in CSF to Blood

Practical Advantages of Measuring NfL in Serum

High NfL Levels and Potential Treatment Decision

Low or Continuously High NfL Levels and Potential Treatment Decision

NfL as a Complement to MRI: Summary of Case 1

Real-Life Evidence With NfL in CSF: Influence in Treatment Decision-Making

High NfL Levels and Decision to Initiate Therapy: Czech Republic

High NfL Levels and Decision to Initiate Therapy: Switzerland

High NfL Levels and Decision to Initiate Therapy: United Kingdom

Patient Case 2: Suzanne

Patient Case 2: Suzanne (cont)

Serum NfL Levels as a Predictor of Disease Worsening and Brain and Spinal Cord Atrophy

Practical Use of NfL in the Czech Republic

Hurdles to Overcome in Practical Use of NfL

MRI as a Standardized Biomarker?

Brain Atrophy: Focal Cord and Brain Lesions in RRMS and SPMS

Baseline Tests for Patients Starting on Anti-CD20 Therapy: Infection Screening

Effect of Treatment in Reducing NfL Levels

Concluding Remarks

Concluding Remarks (cont)

Abbreviations

Abbreviations (cont)